Lundbeck hikes guidance on strong start to 2016, beating forecasts

11 May 2016

Shares of Danish CNS specialist Lundbeck (LUND: CO) leapt 7.68% to 253.70 Danish kroner this morning after the company posted strong first-quarter 2016 financial results and said it was raising its full year guidance.

Lundbeck said revenue for the quarter reached 3.77 billion ($580 million), representing an increase of 6% both reported and in local currencies compared to the same period last year. This was ahead of analysts’ estimates of 3.62 billion. Reported earnings before interest and taxes (EBIT) came in at 483 million kroner compared with a loss of 32 million kroner in the like 2015 quarter, and significantly beating estimates of 254 million kroner of analysts polled by Reuters. Reported earnings per share were 0.94 kroner versus -0.41 kroner and core EBIT was 749 million kroner compared with 216 million kroner.

Total revenue have delivered a better performance than expected for the quarter primarily driven by key products - Abilify Maintena (aripiprazole), Brintellix/Trintellix (vortioxetine), Northera (droxidopa), Onfi (clobazam, Rexulti (brexpiprazole)and Xenazine(tetrabenazine).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK